UK markets closed

GenSight Biologics S.A. (0RIM.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
0.4030+0.0050 (+1.26%)
At close: 04:29PM BST
Full screen
Previous close0.3980
Open0.4030
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.4030 - 0.4030
52-week range0.3280 - 2.5300
Volume0
Avg. volume2,025
Market cap114,655
Beta (5Y monthly)2.14
PE ratio (TTM)N/A
EPS (TTM)-0.6330
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    GenSight Biologics Announces the Filing of its 2023 Universal Registration Document

    PARIS, April 18, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2023 Universal Registration Document (URD) in English with the French market authority (Autorités des Marchés Financiers, or AMF) under the reference D.24-0299.

  • Business Wire

    GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update

    PARIS, April 04, 2024--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of March 31, 2024 and provided a business update.

  • Business Wire

    GenSight Biologics Announces its 2024 Financial Calendar

    PARIS, April 04, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calendar for 2024.